Straits Times Index
3,330.01 -8.93 (-0.27%) S&P 500
5,291.34 +7.94 (+0.15%) Dow
38,711.29 +140.26 (+0.36%) Nasdaq
16,857.05 +28.38 (+0.17%) Bitcoin USD
70,868.86 +2,271.20 (+3.31%) CMC Crypto 200
1,505.71 +31.97 (+2.17%)
TGTX Jan 2025 35.000 call
| Previous close | 0.6000 |
| Open | 0.5200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 35.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.5200 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireTG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ETNEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024. The fireside chat is scheduled to take place on Wednesday, June 5, 2024, at 1:30 PM ET. A live webcast of the fireside chat wi
- GlobeNewswire
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links. Link to Poster Presentation: A Post-Marketing Study Evaluating the Presence an
Simply Wall St.Despite shrinking by US$192m in the past week, TG Therapeutics (NASDAQ:TGTX) shareholders are still up 131% over 5 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
